Diagnosis → Ophthalmology

Keratitis

Inflammation of the cornea.

Also known as: Corneal infection, Corneal ulcer

Etiology

Cause [43s][eci]

Pathophysiology [43s]

  1. Disruption of corneal epithelial barrier → loss of the primary defense mechanism

    • Contact lens wear, trauma, surgery, ocular surface disease, Vitamin A deficiency

  2. Pathogen adherence and stromal invasion

    • Inflammation --> polymorphonuclear leukocytes and macrophages

    • Inflammatory cells --> Proteases/hydrolase/toxins --> Tissue destruction

    • Starts with epithelial ulceration: Usually seen in HSV → dendritic ulceration

    • Stromal infiltration: Immune-mediated disciform or necrotizing stromal keratitis

  3. Host inflammatory response

    • Corneal edema

    • Leukocyte infiltration

    • Neovascularization

    • Anterior chamber reaction (hypopyon in bacterial/fungal)

    • Severe pain

Risk Factors [eci]

Complications [43s]

Epidemiology

Incidence per 100.000 [oss][pnc][wtb][k1w]

Default

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

Blindness, Blurred vision, Hypoesthesia, Keratic precipitates, Lacrimation, Mucopus, Photophobia, Red eye

Clinical findings

Conjunctival injection

Anamneses

Trauma

Localized findings

Pain
Radiates
Eyes
Onset
Acute (minutes)Subacute (hours)
Pattern
ConstantIncreasing
Provoked by
Palpation
Decreased by
Rest
Quality
SharpBurningAching
Severity
Moderate (4-7)Severe (8-10)
Swelling
Radiates
EyesRegio orbitalis
Onset
Subacute (hours)Gradual (days)
Pattern
ConstantIncreasing
Decreased by
Rest

Approach

Treatment

  1. Remove contact lenses immediately [43s]

  2. Obtain corneal scrapings for smear and culture before starting antimicrobials

  3. Cycloplegic agent (cyclopentolate or atropine 1%)

  4. Xerophthalmia: Vitamin A supplementation

  5. Mild bacterial keratitis

    • Topical fluoroquinolone monotherapy 3–4 times/day

    • Ciprofloxacin 0.3%

    • Ofloxacin 0.3%

    • Levofloxacin 1.5%

    • MRSA: Vancomycin or topical linezolid 0.2%

    • Pseudomonas: Oral doxycycline is added and topical imipenem-cilastatin

    • Nocardia: Topical fortified amikacin (2.5%)

    • Atypical mycobacteria: Topical fortified amikacin (4%) or Clarithromycin (2%)

  6. Severe/central bacterial keratitis (infiltrate >2 mm, stromal melting, hypopyon)

    • Complete coverage against both gram-positive and gram-negative organisms

    • Fortified cefazolin 5%

    • Tobramycin

    • Gentamicin

  7. Protozoal keratitis: Biguanides and pentamidine

  8. Oomycete keratitis: Topical linezolid (0.2%) + topical and oral azithromycin

  9. Fungal keratitis: Albendazole (400 mg twice daily for 3-4 weeks) and topical fumagillin

  10. Viral keratitis: Topical Acyclovir 3% x 5 (+ oral Acyclovir 400 mg x 5)

  11. Herpes zoster ophthalmicus: Oral Acyclovir 800 mg x 5 for 1 week

  12. Local causes --> correction of pathology:

    • Trichiatic lashes: electrolysis of eyelash hair root follicle

    • Distichiasis: lid splitting procedure

    • Entropion: lid everting procedure

    • Giant papillary conjunctivitis: Topical steroids + topical cyclosporine + lubricants

    • Removal of a foreign body

  13. Systemic causes: Topical and oral steroids or methotrexate

  14. Perforated corneal ulcer:

    • Cyanoacrylate tissue adhesive glue or amniotic membrane graft

Differential diagnoses

Blepharitis, Conjunctivitis, Corneal abrasion, Corneal ulcer, Endophthalmitis, Entropion, Foreign body, Glaucoma, Herpes zoster, Iridocyclitis, Keratoconjunctivitis sicca, Nasolacrimal duct obstruction, Periorbital cellulitis, Rosacea, Scleritis, Sebaceous carcinoma, Stevens-Johnson syndrome, Subconjunctival hemorrhage, Toxic epidermal necrolysis


References

[1] Singh P, Gupta A, Tripathy K. Keratitis. [Updated 2023 Aug 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559014/

[2] Ting DSJ, Ho CS, Deshmukh R, Said DG, Dua HS. Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance. Eye (Lond). 2021 Apr;35(4):1084-1101.

[3] Erie JC, Nevitt MP, Hodge DO, Ballard DJ. Incidence of ulcerative keratitis in a defined population from 1950 through 1988. Arch Ophthalmol. 1993 Dec;111(12):1665-71.

[4] Jeng BH, Gritz DC, Kumar AB, Holsclaw DS, Porco TC, Smith SD, Whitcher JP, Margolis TP, Wong IG. Epidemiology of ulcerative keratitis in Northern California. Arch Ophthalmol. 2010 Aug;128(8):1022-8.

[5] Ting DSJ, Ho CS, Cairns J, Elsahn A, Al-Aqaba M, Boswell T, Said DG, Dua HS. 12-year analysis of incidence, microbiological profiles and in vitro antimicrobial susceptibility of infectious keratitis: the Nottingham Infectious Keratitis Study. Br J Ophthalmol. 2021 Mar;105(3):328-333.

[6] Koh YY, Sun CC, Hsiao CH. Epidemiology and the Estimated Burden of Microbial Keratitis on the Health Care System in Taiwan: A 14-Year Population-Based Study. Am J Ophthalmol. 2020 Dec;220:152-159.

[7] Stapleton F. The epidemiology of infectious keratitis. Ocul Surf. 2023 Apr;28:351-363.

Scroll to top